[go: up one dir, main page]

DE60017888D1 - Dinatrium-salze, monohydrate und ethanol-solvate - Google Patents

Dinatrium-salze, monohydrate und ethanol-solvate

Info

Publication number
DE60017888D1
DE60017888D1 DE60017888T DE60017888T DE60017888D1 DE 60017888 D1 DE60017888 D1 DE 60017888D1 DE 60017888 T DE60017888 T DE 60017888T DE 60017888 T DE60017888 T DE 60017888T DE 60017888 D1 DE60017888 D1 DE 60017888D1
Authority
DE
Germany
Prior art keywords
ethanol solvate
delivery agents
disodium salt
ethanol
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017888T
Other languages
English (en)
Other versions
DE60017888T2 (de
Inventor
E Bay
K Agarwal
Kiran Chaudhary
Shingai Majuru
M Goldberg
P Russo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Publication of DE60017888D1 publication Critical patent/DE60017888D1/de
Application granted granted Critical
Publication of DE60017888T2 publication Critical patent/DE60017888T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/241,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26Two oxygen atoms, e.g. isatoic anhydride
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60017888T 1999-04-05 2000-04-05 Dinatrium-salze, monohydrate und ethanol-solvate Expired - Lifetime DE60017888T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12775499P 1999-04-05 1999-04-05
US127754P 1999-04-05
US18614200P 2000-03-01 2000-03-01
US18614300P 2000-03-01 2000-03-01
US186143P 2000-03-01
US186142P 2000-03-01
US19128600P 2000-03-21 2000-03-21
US191286P 2000-03-21
PCT/US2000/009390 WO2000059863A1 (en) 1999-04-05 2000-04-05 Disodium salts, monohydrates, and ethanol solvates

Publications (2)

Publication Number Publication Date
DE60017888D1 true DE60017888D1 (de) 2005-03-10
DE60017888T2 DE60017888T2 (de) 2006-01-19

Family

ID=27494697

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017888T Expired - Lifetime DE60017888T2 (de) 1999-04-05 2000-04-05 Dinatrium-salze, monohydrate und ethanol-solvate

Country Status (11)

Country Link
US (6) US20020065255A1 (de)
EP (1) EP1175390B1 (de)
JP (2) JP4588221B2 (de)
AT (1) ATE288415T1 (de)
AU (1) AU4216700A (de)
CA (1) CA2369591C (de)
DE (1) DE60017888T2 (de)
ES (1) ES2235854T3 (de)
IL (4) IL145546A0 (de)
NZ (1) NZ534409A (de)
WO (1) WO2000059863A1 (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610329B2 (en) 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE69925276T2 (de) 1998-07-27 2005-10-06 Emisphere Technologies, Inc. Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TR200100366T2 (tr) 1998-08-07 2001-11-21 Emisphere Technologies, Inc. Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
WO2001051454A1 (en) * 2000-01-13 2001-07-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1299348B1 (de) 2000-06-29 2008-04-09 Emisphere Technologies, Inc. Verbindungen und gemische zur verabreichung eines aktiven agens
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CA2446929C (en) * 2001-06-01 2013-04-09 Novartis Ag Orally administering parathyroid hormone and calcitonin
EP1420827B8 (de) * 2001-08-17 2009-12-23 Novartis AG 5-cnac zur oralen verabreichung von parathormonfragmenten
JP5196701B2 (ja) * 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
JP4508646B2 (ja) 2002-01-09 2010-07-21 エミスフェアー・テクノロジーズ・インク 4−[(4−クロロ−2−ヒドロキシベンゾイル)アミノ]ブタン酸ナトリウムの多形体
AU2003208945B2 (en) 2002-02-20 2008-05-01 Emisphere Technologies, Inc Method for administering GLP-1 molecules
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) * 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
ES2330638T3 (es) 2003-07-11 2009-12-14 Novartis Ag Composiciones farmaceuticas dosificadas en forma oral que contienen un agente de suministro en forma micronizada.
US7749954B2 (en) * 2003-07-23 2010-07-06 Novartis Ag Use of calcitonin in osteoarthritis
DE60325906D1 (de) 2003-08-08 2009-03-05 Amgen Fremont Inc Antikörper gegen parath-hormon (pth) und ihre verwendungen
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
MXPA06001916A (es) 2003-08-20 2006-05-17 Lilly Co Eli Compuestos, metodos y formulaciones para el suministro oral de un compuesto peptidico similar a glucagona (glp)-i o un peptido agonista del receptor de melanocortina 4 (mc4).
EP1658273B1 (de) 2003-08-20 2007-01-03 Eli Lilly And Company Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005115406A2 (en) 2004-04-16 2005-12-08 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
EA013518B1 (ru) * 2004-05-06 2010-06-30 Эмисфире Текнолоджис, Инк. Кристаллические полиморфные формы n-[8-(2-гидроксибензоил)амино]каприлата натрия
KR20070008720A (ko) 2004-05-06 2007-01-17 에미스페어 테크놀로지스, 인코포레이티드 습윤 헤파린의 고체 투여형
KR101193228B1 (ko) * 2004-05-06 2012-10-22 에미스페어 테크놀로지스, 인코포레이티드 모노소듐 n-[8-(2-히드록시벤조일)아미노]카프릴레이트의 결정 다형 형태
CN1953753B (zh) * 2004-05-06 2011-02-09 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
RU2403237C2 (ru) * 2004-05-14 2010-11-10 Эмисфире Текнолоджис, Инк. Составы и смеси для доставки активных агентов
CA2566161C (en) 2004-05-14 2013-10-01 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
NZ597499A (en) 2004-05-14 2013-04-26 Emisphere Tech Inc Compounds and compositions for delivering active agents
CA2566741C (en) 2004-05-19 2014-06-10 Emisphere Technologies, Inc. Acyclovir formulations
BRPI0510906A (pt) * 2004-05-19 2007-11-06 Emisphere Tech Inc composição farmacêutica tópica, composição para administração tópica e seu uso
EP1791553B1 (de) * 2004-07-12 2013-10-23 Emisphere Technologies, Inc. Zusammensetzungen zur abgabe von peptid yy und pyy agonisten
CA2573856A1 (en) 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
AU2005321803B2 (en) * 2004-12-29 2012-02-09 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
PE20070548A1 (es) * 2005-09-19 2007-07-12 Emisphere Tech Inc Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
JP2009515993A (ja) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
US9364502B2 (en) 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
USRE48164E1 (en) 2006-08-31 2020-08-18 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
PT2059260E (pt) * 2006-08-31 2013-09-03 Novartis Ag Composições farmacêuticas compreendendo hgh para distribuição oral
US10875826B2 (en) * 2006-09-07 2020-12-29 Emisphere Technologies, Inc. Process for the manufacture of SNAC (salcaprozate sodium)
CN101621991A (zh) * 2007-03-02 2010-01-06 诺瓦提斯公司 降钙素的口服施用
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
PT2460515T (pt) 2007-08-09 2017-04-27 Novartis Ag Composições orais de calcitonina e suas aplicações
PT2215047E (pt) 2007-11-02 2014-01-20 Emisphere Tech Inc Processo para o tratamento da deficiência de vitamina b12
EP2676956A1 (de) * 2008-08-01 2013-12-25 Purdue Pharma L.P. Tetrahydropyridinyl- und Dihydropyrrolylverbindungen und ihre Verwendung
CN104922655A (zh) 2009-02-06 2015-09-23 加利福尼亚大学董事会 钙结合剂诱导毛发生长和/或甲生长
CN102369018B (zh) 2009-03-12 2016-08-03 关键生物科学有限公司 糖尿病和代谢综合征的治疗
WO2011017346A2 (en) 2009-08-03 2011-02-10 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
AU2011220867B2 (en) * 2010-02-24 2014-05-15 Emisphere Technologies, Inc. Oral B12 therapy
US9402864B2 (en) * 2010-06-09 2016-08-02 Emisphere Technologies, Inc. Oral iron deficiency therapy
US10449177B2 (en) 2010-08-19 2019-10-22 Buck Institute For Research On Aging Methods of treating mild cognitive impairment (MCI) and related disorders
WO2012027440A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Hiv core protein specific antibodies and uses thereof
TW201309346A (zh) * 2011-01-05 2013-03-01 Hospira Inc 噴霧乾燥萬古黴素
EP4070801A1 (de) 2011-03-01 2022-10-12 Nutrition 21, LLC Zusammensetzungen aus insulin und chrom zur behandlung und vorbeugung von diabetes, hypoglykämie und verwandten erkrankungen
RU2616511C2 (ru) 2011-11-02 2017-04-17 Кибайосайнс Аг Пептидные аналоги для лечения заболеваний и расстройств
PL3095484T3 (pl) 2011-11-02 2018-10-31 Keybioscience Ag Mimetyki kalcytoniny do leczenia chorób i zaburzeń
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
AU2013302390A1 (en) 2012-08-16 2015-02-26 Ohio State Innovation Foundation Stat3 inhibitors and their anticancer use
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
DK2897620T3 (da) 2012-09-21 2020-08-17 Intensity Therapeutics Inc Fremgangsmåde til behandling af cancer
EP4335505A3 (de) 2012-11-30 2024-06-05 The Regents of The University of California Antikonvulsive aktivität von steroiden
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
AU2014287044B2 (en) * 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
JP6639389B2 (ja) 2013-11-14 2020-02-05 キーバイオサイエンス・アクチエンゲゼルシャフト 疾患および障害を処置するためのカルシトニン模倣体
EP3006045B3 (de) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmazeutische Formulierungen zur oralen Verabreichung von Peptid- oder Proteinarzneimitteln
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
EP3256114A4 (de) 2015-02-09 2018-11-21 Entera Bio Ltd. Behandlung von osteoporose
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
AU2017252575B2 (en) 2016-04-22 2021-11-18 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
SG11201901070YA (en) 2016-08-17 2019-03-28 Entera Bio Ltd Formulations for oral administration of active agents
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2018129200A2 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
KR20200066319A (ko) * 2017-10-05 2020-06-09 리셉터 홀딩스, 인크. 개선된 생체이용률을 갖는 약초 조성물
CA3078549A1 (en) * 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
US11826414B2 (en) 2017-10-23 2023-11-28 Cz Biohub Sf, Llc Measurement of afucosylated IgG Fc glycans and related vaccination methods
EP3773475A1 (de) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmazeutische zusammensetzungen zur transmukosalen abgabe von therapeutischen peptiden und proteinen
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
JP7566336B2 (ja) 2018-11-19 2024-10-15 スポーク・サイエンシズ・インコーポレイテッド カンナビノイド由来組成物の吸収変動を低減するn-アシル化脂肪アミノ酸
CN111057165A (zh) * 2020-01-13 2020-04-24 苏州健飞肠衣有限公司 一种高纯度肝素钠的制备方法
US20240041983A1 (en) 2020-09-07 2024-02-08 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
US11667614B2 (en) 2021-04-16 2023-06-06 Navinta III Inc. Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
EP4323330A1 (de) 2021-04-16 2024-02-21 Navinta III Inc Verfahren zur herstellung von hochreiner salcaprozinsäure und pharmazeutisch akzeptablen salzen daraus
CA3216091A1 (en) 2021-04-22 2022-10-27 Henrik Oerum Oral delivery of oligonucleotides
PH12023553506A1 (en) 2021-07-16 2024-04-29 Novo Nordisk As Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
CN119156221A (zh) 2022-03-03 2024-12-17 西普鲁梅有限公司 治疗性肽和蛋白质的改进的口服药物制剂
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024211393A2 (en) 2023-04-04 2024-10-10 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES369853A1 (es) * 1969-07-24 1971-07-16 Bama S A Lab Procedimiento para la obtencion de derivados del acido ep- silon-amino-caproico.
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
US4061466A (en) * 1974-10-16 1977-12-06 Ingvar Gosta Holger Sjoholm Biologically active composition and the use thereof
DE2500157C2 (de) * 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
DE2532420A1 (de) * 1975-07-19 1977-02-03 Boehringer Mannheim Gmbh Phenylessigsaeure-derivate und verfahren zu ihrer herstellung
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
NZ196349A (en) 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
US4442090A (en) * 1980-11-09 1984-04-10 Kyoto Yakuhin Kogyo Kabushiki Kaisha Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
GB2092136B (en) * 1981-01-17 1985-06-05 Mitsui Toatsu Chemicals Production of n-substituted amide compounds
JPS58140026A (ja) * 1982-01-14 1983-08-19 Toyo Jozo Co Ltd 吸収性良好な製剤
FR2509175B1 (fr) 1981-03-06 1987-01-16 Toyo Jozo Kk Preparation therapeutique ayant d'excellentes proprietes d'absorption
US4499299A (en) * 1981-12-30 1985-02-12 Ici Americas Inc. Pharmaceutically active phenylcarboxylic acid derivatives
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
US4393192A (en) * 1982-12-21 1983-07-12 The Standard Oil Company Crystalline copolymers prepared from N,N'-terephthaloyldi-beta-alanine and a glycol
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4757066A (en) * 1984-10-15 1988-07-12 Sankyo Company Limited Composition containing a penem or carbapenem antibiotic and the use of the same
CA1234561A (en) 1985-06-26 1988-03-29 Kenneth M. White Profiled body roller-reamer stabilizer
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US4689182A (en) 1985-12-20 1987-08-25 Warner-Lambert Company Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
JPH0725725B2 (ja) * 1987-07-23 1995-03-22 保土谷化学工業株式会社 ベンズアミド誘導体
FR2636238B1 (fr) * 1988-09-14 1994-01-21 Morelle Jean Nouvelles compositions antisudorales
GB8823731D0 (en) 1988-10-10 1988-11-16 Smith Kline French Lab Biologically active compounds
FR2639395B1 (fr) 1988-11-18 1991-02-15 Rockwell Cim Dispositif d'accouplement entre une vitre et un mecanisme de leve-vitre a bras oscillants dans un vehicule automobile
JPH02239980A (ja) 1989-03-15 1990-09-21 Fuji Photo Film Co Ltd 感熱記録材料
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US6221367B1 (en) * 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
HU211995B (en) 1992-06-30 1996-01-29 Gyogyszerkutato Intezet Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
EP0696208B1 (de) * 1993-04-22 2001-08-22 Emisphere Technologies, Inc. Orale darreichungsform
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
SI9720025A (sl) * 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
GB2314189B (en) 1996-06-14 2000-08-09 Mars Inc Coin handling apparatus
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5776888A (en) * 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
ES2263428T3 (es) * 1997-02-07 2006-12-16 Emisphere Technologies, Inc. Compuesto y composicion para agentes activos de administracion.
US6051561A (en) * 1997-02-07 2000-04-18 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AR017426A1 (es) * 1997-12-08 2001-09-05 Smithkline Beecham Corp Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
DE69925276T2 (de) 1998-07-27 2005-10-06 Emisphere Technologies, Inc. Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
TR200100366T2 (tr) 1998-08-07 2001-11-21 Emisphere Technologies, Inc. Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
US6066015A (en) 1998-08-17 2000-05-23 Brown; James D. Method and system for anchoring a buoy via a screw-type anchor
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
BRPI0615081A2 (pt) 2005-08-25 2011-05-03 Univ Arizona State método para modelar migração de célula de cáncer não-linfócita, método para triagem de efeito de um agente quìmico ou biólogo, método para inibir migração de célula de tumor não-linfócita
US20070048725A1 (en) 2005-08-25 2007-03-01 Arrington Ben O'mar Machine perfusion of tissue grafts for transplantation
WO2011048589A2 (en) 2009-10-23 2011-04-28 Ben Gurion University Of The Negev Research And Development Authority Ion exchangers and methods of use thereof

Also Published As

Publication number Publication date
EP1175390A4 (de) 2002-09-04
US8207227B2 (en) 2012-06-26
US20110251125A1 (en) 2011-10-13
JP2002541132A (ja) 2002-12-03
IL180118A (en) 2010-12-30
IL145546A (en) 2007-10-31
IL166158A0 (en) 2006-01-15
EP1175390A1 (de) 2002-01-30
AU4216700A (en) 2000-10-23
WO2000059863A1 (en) 2000-10-12
IL180118A0 (en) 2007-06-03
US8003697B2 (en) 2011-08-23
CA2369591C (en) 2011-06-14
US8658695B2 (en) 2014-02-25
US20020065255A1 (en) 2002-05-30
US7384982B2 (en) 2008-06-10
US20080269134A1 (en) 2008-10-30
ATE288415T1 (de) 2005-02-15
IL145546A0 (en) 2002-06-30
HK1045680A1 (en) 2002-12-06
EP1175390B1 (de) 2005-02-02
US20120264834A1 (en) 2012-10-18
DE60017888T2 (de) 2006-01-19
NZ534409A (en) 2006-03-31
JP4588221B2 (ja) 2010-11-24
JP2005068161A (ja) 2005-03-17
IL166158A (en) 2010-12-30
JP4642435B2 (ja) 2011-03-02
CA2369591A1 (en) 2000-10-12
US20040106825A1 (en) 2004-06-03
US7659311B2 (en) 2010-02-09
US20100099621A1 (en) 2010-04-22
ES2235854T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
DE60017888D1 (de) Dinatrium-salze, monohydrate und ethanol-solvate
CY1113969T1 (el) Ανευ-αλβουμινης συνταγοποιησεις παραγοντα viii
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
DE60031999D1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
RU2008123380A (ru) Фармацевтическая композиция
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
RU2009136303A (ru) Пероральное введение кальцитонина
JP2004521123A5 (de)
TW200744993A (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
AR013157A1 (es) Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion
RU2005105691A (ru) Пероральное введение кальцитонина
NO955067D0 (no) FVII/TF peptider
RS63804A (en) Stable salts of o-acetylsalicylic acid containing basic amino acids ii
IL128513A0 (en) Amino acid ester containing azole antifungals
AR044852A1 (es) Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
RU2004126145A (ru) N-{[(2s)-4-(3,4-дифторбензил)морфолин-2ил]-метил}-2-{3- [(метилсульфонил)амино]фени л}ацетамид в качестве антагониста ccr-3 для лечения восполительных состояний
UY26365A1 (es) Sales de disodio, monohidratos, solvatos de etanol para la liberación de agentes activos
AR036219A1 (es) Sales de disodio, monohidratos, solvatos de etanol para la liberacion de agentes activos
TH51556A (th) เกลือไดโซเดียม โมโนไฮเดรต และ เอธานอลซอลเวต สำหรับการส่งมอบตัวกระทำที่ว่องไว

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EMISPHERE TECHNOLOGIES, INC., CEDAR KNOLLS, N., US